Related Experiment Video
Updated: May 12, 2026

In vitro Functional Characterization of Mouse Colorectal Afferent Endings
Published on: January 21, 2015
Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group
E Falletto1, E Ganio, G Naldini
1Department of Surgery, Città della Scienza e della Salute, San Giovanni Battista Hospital, Corso Bramante 88, Turin, Italy, ezio.falletto@tin.it.
Italian experts reached a national consensus on sacral neuromodulation (SNM) for bowel dysfunction, establishing guidelines for patient selection, management, and treatment protocols.
Area of Science:
- Gastroenterology and Urology
- Neuromodulation Therapies
- Clinical Practice Guidelines
Background:
- Italian centers experienced in sacral neuromodulation (SNM) convened to standardize clinical practice for bowel dysfunction.
- The goal was to develop a consensus statement on SNM indications and patient management strategies.
Purpose of the Study:
- To define current clinical practice for SNM in Italy.
- To produce a consensus statement on SNM indications and patient management.
- To establish national guidelines for SNM in bowel dysfunction.
Main Methods:
- A questionnaire on SNM clinical practice was distributed to 50 Italian colonproctologists.
- Expert opinions were gathered using a 5-point Likert scale, with data weighted by experience.
- A follow-up meeting and literature review were conducted to reach agreement on critical aspects.
Main Results:
- The study reviewed patient selection, diagnostics, implantation, follow-up, and result evaluation for SNM.
- An algorithm for patient management in bowel dysfunction was developed.
- Strategies for managing treatment failure were discussed.
Conclusions:
- Substantial national consensus was achieved on key aspects of SNM therapy for bowel dysfunction.
- The recommendations serve as national guidelines.
- These guidelines are relevant for international SNM implantation centers.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome
Gastrointestinal Motility Disorders
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
